Triggers and oncologic outcome of salvage radical prostatectomy, salvage radiotherapy and active surveillance after focal therapy of prostate cancer.
Aged
High-Intensity Focused Ultrasound Ablation
Humans
Kaplan-Meier Estimate
Male
Middle Aged
Multiparametric Magnetic Resonance Imaging
Multivariate Analysis
Neoplasm Recurrence, Local
/ diagnostic imaging
Progression-Free Survival
Prostate-Specific Antigen
/ blood
Prostatectomy
Prostatic Neoplasms
/ diagnostic imaging
Radiotherapy
Regression Analysis
Salvage Therapy
Watchful Waiting
Focal therapy
Hemi-ablation
High-intensity focused ultrasound
Multiparametric magnetic resonance imaging
Partial gland ablation
Prostate neoplasms
Salvage therapy
Journal
World journal of urology
ISSN: 1433-8726
Titre abrégé: World J Urol
Pays: Germany
ID NLM: 8307716
Informations de publication
Date de publication:
Oct 2021
Oct 2021
Historique:
received:
14
02
2021
accepted:
10
04
2021
pubmed:
22
4
2021
medline:
19
2
2022
entrez:
21
4
2021
Statut:
ppublish
Résumé
Due to the tissue preserving approach of focal therapy (FT), local cancer relapse can occur. Uncertainty exists regarding triggers and outcome of salvage strategies. Patients with biopsy-proven prostate cancer (PCa) after FT for localized PCa from 2011 to 2020 at eight tertiary referral hospitals in Germany that underwent salvage radical prostatectomy (S-RP), salvage radiotherapy (S-RT) or active surveillance (AS) were reported. Prostate specific antigen (PSA) changes, suspicious lesions on mpMRI and histopathological findings on biopsy were analyzed. A multivariable regression model was created for adverse pathological findings (APF) at S-RP specimen. Kaplan-Meier curves were generated to determine oncological outcomes. A total of 90 men were included. Cancer relapse after FT was detected at a median of 12 months (IQR 9-16). Of 50 men initially under AS 13 received S-RP or S-RT. In total, 44 men underwent S-RP and 13 S-RT. At cancer relapse 17 men (38.6%) in the S-RP group [S-RT n = 4 (30.8%); AS n = 3 (6%)] had ISUP > 2. APF (pT ≥ 3, ISUP ≥ 3, pN + or R1) were observed in 23 men (52.3%). A higher ISUP on biopsy was associated with APF [p = 0.006 (HR 2.32, 97.5% CI 1.35-4.59)] on univariable analysis. Progression-free survival was 80.4% after S-RP and 100% after S-RT at 3 years. Secondary therapy-free survival was 41.7% at 3 years in men undergoing AS. Metastasis-free survival was 80% at 5 years for the whole cohort. With early detection of cancer relapse after FT S-RP and S-RT provide sufficient oncologic control at short to intermediate follow-up. After AS, a high secondary-therapy rate was observed.
Identifiants
pubmed: 33881557
doi: 10.1007/s00345-021-03700-x
pii: 10.1007/s00345-021-03700-x
pmc: PMC8519844
doi:
Substances chimiques
Prostate-Specific Antigen
EC 3.4.21.77
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3747-3754Informations de copyright
© 2021. The Author(s).
Références
BJU Int. 2020 Apr;125(4):525-530
pubmed: 31863617
J Urol. 2019 Oct;202(4):717-724
pubmed: 31042109
Eur Urol. 2010 Oct;58(4):567-73
pubmed: 20598436
Eur Urol Focus. 2021 Sep;7(5):1002-1010
pubmed: 33877047
Eur Urol. 2019 Jul;76(1):27-30
pubmed: 30904357
Eur Urol Focus. 2020 Mar 15;6(2):208-211
pubmed: 31053567
World J Urol. 2019 Mar;37(3):397-407
pubmed: 29948045
Eur Urol. 2018 Jul;74(1):84-91
pubmed: 29373215
Eur Urol Open Sci. 2020 Aug 17;21:1-4
pubmed: 34337460
World J Urol. 2019 Aug;37(8):1517-1534
pubmed: 30710157
J Urol. 2019 Jun;201(6):1134-1143
pubmed: 30730409
Abdom Radiol (NY). 2020 Nov;45(11):3882-3895
pubmed: 32447414
J Urol. 2017 Nov;198(5):1069-1076
pubmed: 28551444
World J Urol. 2021 Apr;39(4):1121-1129
pubmed: 32533247
N Engl J Med. 2020 Mar 5;382(10):917-928
pubmed: 32130814
BJU Int. 2017 Oct;120(4):511-519
pubmed: 28267899
Eur Urol. 2016 Jan;69(1):16-40
pubmed: 26427566